Please use this identifier to cite or link to this item:
http://dspace.mediu.edu.my:8181/xmlui/handle/10261/4926| Title: | HIV-1 protease inhibitors: effects on HIV-2 replication and resistance |
| Authors: | Hungarian Scientific Research Fund Instituto de Salud Carlos III (España) Fundación Ramón Areces |
| Keywords: | HIV-1 HIV-2 |
| Publisher: | Elsevier |
| Description: | Novel antiretroviral drugs include protease (PR) inhibitors (e.g. atazanavir, tipranavir and darunavir) that block HIV-1 maturation and show remarkable antiviral potency on drug-resistant isolates. However, the strains used as prototypes in the design of the novel drugs belong to a specific clade (i.e. HIV-1 group M subtype B), which is the most prevalent in developed countries. At the same time, there is an increasing concern about the expansion of other HIV-1 clades as well as other related retroviruses, such as HIV-2. The HIV-2 PR is weakly inhibited by some PR inhibitors (e.g. amprenavir), and little is known of the mutational pathways leading to drug resistance in this virus. The design of specific PR inhibitors targeting HIV-2, or potent drugs showing broad specificity on HIV-1 and HIV-2 clades, remains a major challenge for the future Grants from the Spanish-Hungarian Intergovernmental Science and Technology Cooperation Program (HH2005–0020), the Hungarian Science and Research Fund (OTKA K68288), and the Spanish Ministry of Health (Instituto de Salud Carlos III, RD06/0006/0025), as well as an institutional grant of Fundación Ramón Areces are acknowledged Peer reviewed |
| URI: | http://dspace.mediu.edu.my:8181/xmlui/handle/10261/4926 |
| Other Identifiers: | Trends in Pharmacological Sciences Vol. 29, Issue 1, January 2008, Pages 42-49 0165-6147 (Print) 1873-3735 (Online) http://hdl.handle.net/10261/4926 10.1016/j.tips.2007.10.013 |
| Appears in Collections: | Digital Csic |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.